Liquidia Corp- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Liquidia Corp 公司

Liquidia Corporation 是一家生物制药公司。该公司专注于开发、制造和商业化满足未满足患者需求的产品，重点是罕见的心肺疾病，例如肺动脉高压 (PAH) 和与间质性肺病相关的肺动脉高压 (PH-ILD)。该公司通过其全资运营子公司 Liquidia Technologies, Inc. 和 Liquidia PAH, LLC 开展业务。其专有的 PRINT 技术是一种粒子工程平台，可精确生产均匀的药物颗粒。其主要候选产品是用于治疗 PAH 和 PH-ILD 的 YUTREPIA。YUTREPIA 是一种吸入式曲前列尼尔干粉制剂，采用 PRINT 设计，通过增强深肺输送，同时使用方便的干粉吸入器 (DPI) 并实现比当前吸入疗法标示剂量更高的剂量水平，从而改善曲前列尼尔的治疗特性。

公司简介

公司代码LQDA

公司名称Liquidia Corp

上市日期Jul 26, 2018

成立日期2020

CEODr. Roger A. Jeffs, Ph.D.

员工数量157

证券类型Ordinary Share

年结日Jul 26

公司地址419 Davis Drive

城市MORRISVILLE

上市交易所NASDAQ Capital Market Consolidated

国家United States of America

邮编27560

电话19193284400

网址https://www.liquidia.com/

公司代码LQDA

上市日期Jul 26, 2018

成立日期2020

公司高管

名称

名称/职务

职务

持股

持股变动

Dr. Roger A. Jeffs, Ph.D.

Chief Executive Officer, Director

2.13M

+1.85%

Mr. Russell Schundler, J.D.

General Counsel, Secretary

372.72K

+2.59%

Mr. Rajeev Saggar, M.D.

Chief Medical Officer

266.92K

+3.92%

Mr. Scott Moomaw

Chief Commercial Officer

216.08K

+4.00%

Mr. Jason Adair

Chief Business Officer

161.93K

+5.42%

Mr. Michael Kaseta

Chief Financial Officer, Chief Operating Officer

146.34K

+10.17%

Mr. Damian Degoa

Independent Director

66.11K

+38.55%

Mr. Arthur S. Kirsch

Independent Director

50.40K

+57.49%

Dr. Joanna C. Horobin

Independent Director

18.40K

--

Ms. Katherine (Katie) Rielly-Gauvin

Independent Director

18.40K

--

名称

名称/职务

职务

持股

持股变动

Dr. Roger A. Jeffs, Ph.D.

Chief Executive Officer, Director

2.13M

+1.85%

Mr. Russell Schundler, J.D.

General Counsel, Secretary

372.72K

+2.59%

Mr. Rajeev Saggar, M.D.

Chief Medical Officer

266.92K

+3.92%

Mr. Scott Moomaw

Chief Commercial Officer

216.08K

+4.00%

Mr. Jason Adair

Chief Business Officer

161.93K

+5.42%

Mr. Michael Kaseta

Chief Financial Officer, Chief Operating Officer

146.34K

+10.17%

收入明细

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

暂无数据

地区USD

名称

营收

占比

United States

14.00M

0.00%

业务

地区

暂无数据

股东统计

更新时间: 5月16日周五

持股股东

股东类型

持股股东

占比

Caligan Partners, LP

9.50%

Manning (Paul B.)

7.21%

BlackRock Institutional Trust Company, N.A.

4.91%

Farallon Capital Management, L.L.C.

4.67%

The Vanguard Group, Inc.

4.04%

Other

69.67%

持股股东

占比

Caligan Partners, LP

9.50%

Manning (Paul B.)

7.21%

BlackRock Institutional Trust Company, N.A.

4.91%

Farallon Capital Management, L.L.C.

4.67%

The Vanguard Group, Inc.

4.04%

Other

69.67%

股东类型

持股股东

占比

Hedge Fund

30.69%

Investment Advisor/Hedge Fund

15.97%

Investment Advisor

12.67%

Individual Investor

11.55%

Research Firm

3.48%

Corporation

2.69%

Private Equity

1.78%

Bank and Trust

0.26%

Pension Fund

0.21%

Other

20.70%

机构持股

更新时间: 3月4日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q1

344

64.23M

75.45%

-9.89M

2024Q4

344

63.62M

75.17%

-10.09M

2024Q3

335

73.31M

89.39%

+16.42M

2024Q2

318

66.67M

87.88%

+4.98M

2024Q1

302

59.34M

79.61%

+7.64M

2023Q4

256

48.15M

70.41%

+4.56M

2023Q3

236

40.52M

62.49%

-5.87M

2023Q2

223

41.12M

63.56%

-6.16M

2023Q1

214

42.01M

65.00%

-5.41M

2022Q4

210

41.20M

63.89%

-7.92M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

Caligan Partners, LP

8.12M

9.52%

--

Dec 31, 2024

Manning (Paul B.)

6.15M

7.21%

+316.72K

+5.43%

Sep 30, 2024

BlackRock Institutional Trust Company, N.A.

4.18M

4.9%

+416.76K

+11.07%

Dec 31, 2024

Farallon Capital Management, L.L.C.

3.29M

3.86%

--

Dec 31, 2024

The Vanguard Group, Inc.

3.55M

4.16%

+115.37K

+3.36%

Dec 31, 2024

Findell Capital Management LLC

3.08M

3.61%

-113.54K

-3.56%

Dec 31, 2024

Opaleye Management Inc.

1.70M

1.99%

--

Dec 31, 2024

Jeffs (Roger A)

2.19M

2.56%

+206.98K

+10.46%

Jan 14, 2025

Legend Aggregator LP

1.86M

2.18%

-5.32M

-74.10%

Dec 31, 2024

State Street Global Advisors (US)

1.81M

2.12%

-363.63K

-16.72%

Dec 31, 2024

持股ETF

更新时间: 6月6日周五

机构名称

占比

Invesco Pharmaceuticals ETF

2.76%

Invesco Dorsey Wright Healthcare Momentum ETF

1.97%

SPDR S&P Pharmaceuticals ETF

1.71%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.11%

ALPS Medical Breakthroughs ETF

1.08%

Virtus LifeSci Biotech Clinical Trials ETF

1.01%

iShares U.S. Pharmaceuticals ETF

0.3%

First Trust Small Cap Growth AlphaDEX Fund

0.27%

SPDR S&P Kensho New Economies Composite ETF

0.22%

iShares Micro-Cap ETF

0.21%

Invesco Pharmaceuticals ETF

占比2.76%

Invesco Dorsey Wright Healthcare Momentum ETF

占比1.97%

SPDR S&P Pharmaceuticals ETF

占比1.71%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比1.11%

ALPS Medical Breakthroughs ETF

占比1.08%

Virtus LifeSci Biotech Clinical Trials ETF

占比1.01%

iShares U.S. Pharmaceuticals ETF

占比0.3%

First Trust Small Cap Growth AlphaDEX Fund

占比0.27%

SPDR S&P Kensho New Economies Composite ETF

占比0.22%

iShares Micro-Cap ETF

占比0.21%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Liquidia Corp

13.100USD

Liquidia Corp

13.100

概览

公司